KMT2A
Histone-lysine N-methyltransferase 2A
As of the edition of 20 October 2026, KMT2A (histone-lysine N-methyltransferase 2A, UniProt Q03164) has 1 drug tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q03164
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 60
- Disease areas
- Blood and lymph; Cancer; Immune system; Digestive system; Infections
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Revumenib | Marketed | Phase 3 | Ends 2037 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |